Security key
640268306
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 14,405,809
- Total 13F value
- $819,769,158
- Share change
- +6,760,950
- Put/Call ratio
- 172%
- SEC-reported price per share
- $56.90
- Number of holders
- 143
- Value change
- +$416,306,829
- Number of buys
- 104
- Number of sells
- 45
- Shares outstanding
- 28,687,922
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
143
Top holders
10
NKTR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
NEKTAR THERAPEUTICS SEC filings
NEKTAR THERAPEUTICS company facts
Broader feeds
Reporting periods
Holder history for CUSIP 640268306
Recent filing periods:
Ownership snapshot
Top reported holders of NKTR - NEKTAR THERAPEUTICS - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
3/4/5
Lead comparable stake: 7.4%
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-6 of 15 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 7.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
7.4%
EVENTIDE ASSET MANAGEMENT, LLC
3.6%
INTEGRATED CORE STRATEGIES (US) LLC
3%
Nantahala Capital Management, LLC
2.2%
BlackRock, Inc.
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
7.4%
|
$32,978,662
1,276,595 shares
|
$0 | 01 Jul 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
|
3.6%
|
$4,921,000
6,650,000 shares
|
$0 | 31 Dec 2024 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
3%
|
$32,489,559
570,994 shares
|
-$20,590,346 | 30 Sep 2025 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
2.2%
|
$23,813,902
418,522 shares
|
-$16,571,499 | 30 Sep 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
1.6%
from 13D/G
|
$10,729,447
415,226 shares
|
— | 30 Jun 2025 |
| Deep Track Capital, LP |
3/4/5
13D/G
10%+ Owner
|
1.1%
from 13D/G
|
$32,635,810
18,344,000 shares
|
— | 10 May 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
143
Shares
14,405,809
Rows available
143
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
100
Q3 2025 holders
143
Holder diff
43
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend